Literature DB >> 7817195

[Osteosynthesis of proximal femoral fractures with the modular interlocking system of unreamed AO femoral intramedullary nail. Initial clinical results].

R Hoffmann1, N P Südkamp, C A Müller, M Schütz, N P Haas.   

Abstract

The unreamed femoral nail system (UFN) features highly versatile proximal interlocking options for the treatment of a wide range of femoral fracture patterns and combinations. Besides standard interlocking modes for diaphyseal fractures, special interlocking options for subtrochanteric fractures and ipsilateral neck/shaft fractures are available. Two aiming arms can be attached to the insertion handle of the nail in a modular fashion. The standard aiming arm is designed for transverse static or dynamic locking. The special aiming arm permits spiral blade, 130 degrees, and miss-a-nail interlocking. From August 1992 to July 1994, in 10 out of 55 UFN implantations the special interlocking options were used. In 9 subtrochanteric fractures the spiral blade interlocking and in one ipsilateral neck/shaft fracture the miss-a-nail cancellous screw interlocking was applied. ASIF type A fractures with closed soft tissue damage prevailed. Fracture healing was uneventful and no implant complications or loss of reduction have been observed.

Entities:  

Mesh:

Year:  1994        PMID: 7817195

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  2 in total

1.  Distal humeral plating of an intramedullary nail periprosthetic fracture using a miss-a-nail technique: a case report.

Authors:  Khaled M Sarraf; Ravi Singh; Steven A Corbett
Journal:  Cases J       Date:  2009-05-29

2.  [Subtrochanteric femur fractures-epidemiology, surgical procedures, influence of time to surgery and comorbidities on complications : A risk-adjusted regression analysis of routine data from 2124 cases].

Authors:  C M Müller-Mai; D Deitert; S Hörter; U S Schulze Raestrup; C Zwillich; R Smektala
Journal:  Chirurg       Date:  2021-03       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.